Novartis’s highly anticipated delpacibart etedesiran (del-desiran), a novel therapy acquired through its substantial investment in Avidity Biosciences, has unfortunately failed to achieve its primary efficacy endpoint in the crucial HARBOR Phase III clinical trial for myotonic dystrophy type 1 (DM1). This outcome represents a significant blow to Novartis’s pipeline, particularly as the pharmaceutical giant grapples with upcoming patent expiries on key blockbuster drugs and seeks to bolster its portfolio with innovative treatments.
The failure of del-desiran in the HARBOR study, a late-stage trial designed to evaluate its effectiveness and safety against a placebo in 150 patients diagnosed with DM1, casts a shadow over the ambitious $12 billion acquisition of Avidity Biosciences. Analysts had previously identified the success of the HARBOR study as a critical justification for the substantial price tag associated with the Avidity deal. The trial, which spanned 54 weeks, focused on measuring improvements in a specific clinical metric known as video hand opening time (vHOT). Intravenously administered del-desiran, an antibody-oligonucleotide conjugate (AOC) designed to target the underlying genetic cause of DM1, did not demonstrate a statistically significant improvement in vHOT compared to placebo, thus missing the study’s primary objective.
This setback for del-desiran adds to a series of recent challenges for Novartis’s pipeline development. The company recently experienced another significant disappointment with the failure of its lipoprotein a Lp(a)-reducing drug, pelacarsen, in the closely watched Phase III Lp(a)HORIZON trial. These consecutive late-stage clinical trial misses raise concerns about Novartis’s ability to replenish its product offerings and maintain its projected growth trajectory in the coming years, especially in light of the impending loss of exclusivity for multi-billion dollar drugs such as Entresto and Cosentyx.
Main Facts: Del-Desiran’s Disappointing HARBOR Trial Results
The core of the news revolves around the disappointing outcome of the HARBOR study (NCT06411288). This Phase III trial investigated the efficacy and safety of delpacibart etedesiran (del-desiran) in adult patients diagnosed with myotonic dystrophy type 1 (DM1). The study enrolled 150 participants and was designed to assess the drug’s performance over a 54-week treatment period, comparing it against a placebo.
Key findings from the HARBOR study include:
- Missed Primary Endpoint: Del-desiran failed to achieve a statistically significant improvement in the primary endpoint of video hand opening time (vHOT) when compared to placebo. vHOT is a crucial clinical measure used to assess the delay in a patient’s ability to relax their hand muscles after a forceful contraction, a common symptom of muscle wasting disorders like DM1.
- Demonstrated Some Clinical Activity: Despite missing the primary endpoint, Novartis has indicated that del-desiran showed some signs of clinical activity in secondary endpoints and exploratory analyses. However, the company has yet to provide specific details regarding these findings. The HARBOR study’s secondary objectives included evaluating the drug’s impact on hand grip strength, gait speed (walking and running ability), overall muscle strength, and daily functioning.
- Patient Population: The study focused on patients with myotonic dystrophy type 1 (DM1), a rare genetic disorder characterized by progressive skeletal muscle wasting. DM1 is considered the most common form of muscular dystrophy in adults, affecting approximately 9.27 in every 100,000 individuals, particularly those of European ancestry. Currently, patients with DM1 rely on symptomatic and supportive treatments due to the absence of approved disease-modifying therapies.
- Acquisition Rationale: The success of the HARBOR study was widely considered by analysts to be a critical factor in justifying the $12 billion price tag of Novartis’s acquisition of Avidity Biosciences. This acquisition aimed to secure rights to del-desiran, along with other promising candidates like delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD) and delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD).
Chronology of Events and Strategic Context
The failure of del-desiran in the HARBOR study is not an isolated incident for Novartis. It follows closely on the heels of another significant disappointment in their late-stage pipeline, highlighting a pattern of challenges in bringing novel therapies to market.
- 2025: Novartis executes a landmark $12 billion acquisition of Avidity Biosciences. This strategic move grants Novartis global rights to Avidity’s pioneering antibody-oligonucleotide conjugate (AOC) platform and its lead drug candidates, including del-desiran, del-zota, and del-brax. The acquisition is positioned as a significant step towards bolstering Novartis’s rare disease and genetic medicine portfolio.
- July 2026: Jefferies analysts issue a research note highlighting the critical importance of the HARBOR study’s upcoming results. They emphasize that a positive outcome is essential to validate the substantial investment made in the Avidity acquisition. The analysts also point out the potential impact of a negative readout on Novartis’s projected mid-single digit growth targets up to 2030, suggesting that further Mergers and Acquisitions (M&A) might be necessary to achieve these financial goals.
- Recent Past (Unspecified but prior to current news): Novartis’s investigational drug, pelacarsen, designed to reduce lipoprotein a (Lp(a)), fails to meet its primary endpoint in the Phase III Lp(a)HORIZON trial. This failure represents another significant setback for Novartis’s cardiovascular pipeline.
- Present (Date of News Publication): Novartis announces that del-desiran has failed to meet its primary endpoint in the Phase III HARBOR study for myotonic dystrophy type 1 (DM1). The company states that it will continue to analyze the full dataset to determine the future development path for del-desiran.
- Future: Novartis faces the looming challenge of multiple patent expiries for its established blockbuster drugs, including Entresto (sacubitril/valsartan) for heart failure and Cosentyx (secukinumab) for autoimmune conditions. These patent cliffs necessitate a robust pipeline of new therapies to offset anticipated revenue declines.
This timeline underscores the pressure Novartis is under to deliver successful clinical trial outcomes. The strategic rationale behind the Avidity acquisition was heavily contingent on the success of its drug candidates, and the HARBOR study’s failure complicates this narrative significantly.
Supporting Data and Scientific Rationale
Myotonic dystrophy type 1 (DM1) is a devastating genetic disorder that affects approximately 9.27 out of every 100,000 individuals, making it the most prevalent form of muscular dystrophy among adults. The disease is characterized by a progressive decline in muscle strength and function, leading to significant disability and reduced quality of life. Current treatment options for DM1 are limited to symptomatic and supportive care, highlighting the urgent unmet medical need for disease-modifying therapies.
The scientific premise behind del-desiran lies in its innovative approach as an antibody-oligonucleotide conjugate (AOC). This dual-action technology is designed to combine the targeting precision of an antibody with the gene-silencing capabilities of an oligonucleotide. In the case of DM1, del-desiran is engineered to bind to specific receptors on muscle cells and then deliver an antisense oligonucleotide designed to reduce the toxic accumulation of toxic RNA transcripts caused by the underlying genetic mutation (a CTG repeat expansion in the DMPK gene). This mechanism of action aims to address the root cause of the disease, offering the potential for a truly disease-modifying effect.
The vHOT (video hand opening time) endpoint, while a standardized measure, reflects a functional deficit experienced by many DM1 patients. Their myotonia, or inability to quickly relax muscles, significantly impacts their daily activities, including simple tasks like releasing their grip. Therefore, a significant improvement in vHOT would have been a strong indicator of the drug’s ability to alleviate a key symptom of the disease.
While the primary endpoint was missed, Novartis’s statement about "signs of clinical activity in both secondary endpoints and exploratory analyses" warrants further attention. These secondary endpoints, including grip strength, gait speed, and overall muscle strength, are also critical indicators of disease progression and patient well-being. A detailed analysis of this data could potentially reveal a subset of patients who benefited from del-desiran or identify specific aspects of the disease that the drug may influence, even if not to the degree required for regulatory approval based on the primary endpoint.
The rarity of DM1 also presents unique challenges for clinical trial design and interpretation. Smaller patient populations can lead to greater variability in results, and the long-term progression of the disease can make it difficult to discern drug effects over shorter trial durations. Nevertheless, the failure to meet a primary endpoint in a Phase III trial, especially one that was crucial for validating a significant acquisition, is a substantial setback.
Official Responses and Future Directions
The disappointing news from the HARBOR study has elicited measured responses from Novartis, emphasizing a commitment to thorough analysis and a cautious approach to future development.
Shreeram Aradhye, Chief Medical Officer (CMO) at Novartis, stated: "We will continue to explore the full HARBOR dataset to determine next steps for the del-desiran programme." This statement indicates that while the primary endpoint was missed, Novartis is not abandoning the drug entirely without a comprehensive review of all available data. The company’s leadership acknowledges the significance of the findings and the need for a deep dive into both the efficacy and safety profiles observed during the trial.
The implications of this miss are profound for both Novartis and the patient community. For Novartis, it represents a significant financial and strategic blow. The $12 billion spent on Avidity Biosciences was predicated on the success of its pipeline, with del-desiran being a flagship candidate. The failure to deliver a positive result in HARBOR calls into question the valuation of the acquisition and puts further pressure on Novartis to find new avenues for growth.
Regarding the wider pipeline and patent expiries, the news compounds existing concerns. Analysts at Jefferies, who had previously flagged the HARBOR study’s results as a critical determinant for justifying the acquisition price, have also highlighted the potential impact on Novartis’s mid-single digit growth targets up to 2030. Without the expected contributions from drugs like del-desiran, the company may need to pursue additional M&A activity or accelerate the development of other pipeline assets to compensate for the anticipated revenue decline from patent expirations.
However, there are some glimmers of hope for Novartis’s pipeline. The company recently celebrated a resounding late-stage success with its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, which demonstrated positive Phase III results in relapsing multiple sclerosis (RMS). This success offers a counterpoint to the recent disappointments and underscores Novartis’s continued commitment to innovation in other therapeutic areas.
The future development of del-desiran will hinge on the detailed analysis of the HARBOR dataset. If the secondary and exploratory endpoints reveal compelling evidence of clinical benefit in specific patient populations or for certain aspects of DM1, Novartis might consider pursuing a more targeted development strategy or seeking regulatory pathways for niche indications. Alternatively, the company may decide to deprioritize del-desiran and reallocate resources to other promising candidates within its portfolio or to further M&A opportunities.
For patients with DM1, the news is undoubtedly disheartening. The lack of approved disease-modifying therapies means that any promising new treatment candidate carries significant weight. The failure of del-desiran to meet its primary endpoint leaves the community still waiting for a breakthrough therapy. Novartis’s commitment to further analyzing the data offers a faint hope that some benefit might still be gleaned, but the path forward for del-desiran, and indeed for Novartis’s rare disease ambitions, is now more uncertain than ever.
About the Author
